FORBES-TATE for NOVARTIS, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Health Issues HCR
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Medicare/Medicaid MMM
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Trade (domestic/foreign) TRD
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Budget/Appropriations BUD
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| JEFFREY STRUNK | — |
| BARRETT THORNHILL | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.